CapsoVision's (CV) Sell (E-) Rating Reiterated at Weiss Ratings

Key Points

• CapsoVision's stock has a "sell (e-)" rating reaffirmed by Weiss Ratings, while other brokerages have issued mixed ratings, including a "hold" and a "speculative buy" with price targets ranging from $5.00 to $6.00.
• The company's shares experienced a 2.3% decline to $4.60, with a trading volume significantly below its average, and it reported a loss of ($2.02) EPS against a consensus estimate of ($0.11).
• CapsoVision focuses on developing advanced imaging and AI technologies for capsule endoscopy solutions to diagnose gastrointestinal tract abnormalities.

CapsoVision (NASDAQ:CV - Get Free Report)'s stock had its "sell (e-)" rating reaffirmed by investment analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Several other brokerages have also issued reports on CV. Wall Street Zen upgraded shares of CapsoVision to a "hold" rating in a research note on Sunday, July 13th. Benchmark began coverage on shares of CapsoVision in a research note on Monday, July 28th. They set a "speculative buy" rating and a $5.00 price objective for the company. Finally, Roth Capital set a $6.00 price objective on shares of CapsoVision and gave the company a "buy" rating in a research note on Monday, July 28th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $5.50.

CapsoVision Trading Down 2.3%

Shares of NASDAQ:CV traded down $0.11 on Wednesday, hitting $4.60. The company had a trading volume of 30,457 shares, compared to its average volume of 166,035. The stock's 50-day moving average is $4.17. CapsoVision has a 1 year low of $3.43 and a 1 year high of $5.72.

CapsoVision (NASDAQ:CV - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($2.02) EPS for the quarter, missing the consensus estimate of ($0.11) by ($1.91). The firm had revenue of $3.32 million for the quarter, compared to analysts' expectations of $3.20 million.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.